DK3612237T3 - Genterapi - Google Patents

Genterapi Download PDF

Info

Publication number
DK3612237T3
DK3612237T3 DK18719544.1T DK18719544T DK3612237T3 DK 3612237 T3 DK3612237 T3 DK 3612237T3 DK 18719544 T DK18719544 T DK 18719544T DK 3612237 T3 DK3612237 T3 DK 3612237T3
Authority
DK
Denmark
Prior art keywords
genteraphy
Prior art date
Application number
DK18719544.1T
Other languages
English (en)
Inventor
Anna Christina Kajaste-Rudnitski
Carolina Petrillo
Bernhard Rudolf Gentner
Luigi Naldini
Pietro Genovese
Giulia Schiroli
Original Assignee
Ospedale San Raffaele Srl
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele Srl, Fond Telethon filed Critical Ospedale San Raffaele Srl
Application granted granted Critical
Publication of DK3612237T3 publication Critical patent/DK3612237T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18719544.1T 2017-04-21 2018-04-20 Genterapi DK3612237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1706394.2A GB201706394D0 (en) 2017-04-21 2017-04-21 Gene Therapy
PCT/EP2018/060237 WO2018193118A1 (en) 2017-04-21 2018-04-20 Gene therapy

Publications (1)

Publication Number Publication Date
DK3612237T3 true DK3612237T3 (da) 2021-12-06

Family

ID=58795636

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18719544.1T DK3612237T3 (da) 2017-04-21 2018-04-20 Genterapi

Country Status (18)

Country Link
US (2) US11964027B2 (da)
EP (2) EP3612237B1 (da)
JP (2) JP7443063B2 (da)
CN (1) CN110769860B (da)
AU (1) AU2018253958B2 (da)
CA (1) CA3060128A1 (da)
DK (1) DK3612237T3 (da)
ES (1) ES2900560T3 (da)
GB (1) GB201706394D0 (da)
HR (1) HRP20211803T1 (da)
HU (1) HUE056570T2 (da)
IL (1) IL270032B2 (da)
LT (1) LT3612237T (da)
PL (1) PL3612237T3 (da)
PT (1) PT3612237T (da)
RS (1) RS62619B1 (da)
SI (1) SI3612237T1 (da)
WO (1) WO2018193118A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850484C (en) * 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
WO2023077107A1 (en) * 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202208550D0 (en) * 2022-06-10 2022-07-27 Ospedale San Raffaele Srl Cyclosporin h and uses thereof
GB202209098D0 (en) * 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
JP2025530652A (ja) 2022-08-11 2025-09-17 フォンダジオン テレソン イーティーエス 遺伝子治療
EP4602153A1 (en) 2022-10-11 2025-08-20 Fondazione Telethon ETS 3d cell culture methods
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
ATE368122T1 (de) 1999-04-29 2007-08-15 Cell Genesys Inc Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
JP2006513153A (ja) 2002-10-09 2006-04-20 ロランティス リミテッド 免疫機能の調節
DE602004030105D1 (de) * 2003-05-05 2010-12-30 Virxsys Corp Erhöhte transduktion mit abc-transportersubstratenhemmern
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
WO2014109728A1 (en) 2013-01-11 2014-07-17 The Scripps Research Institute Methods and compositions for enchancing transduction efficiency of retroviral vectors
ES2747951T3 (es) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
GB201407322D0 (en) * 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Also Published As

Publication number Publication date
WO2018193118A1 (en) 2018-10-25
US12485187B2 (en) 2025-12-02
CA3060128A1 (en) 2018-10-25
US20210121579A1 (en) 2021-04-29
JP2024045128A (ja) 2024-04-02
CN110769860A (zh) 2020-02-07
JP2020517253A (ja) 2020-06-18
EP3612237A1 (en) 2020-02-26
RS62619B1 (sr) 2021-12-31
HRP20211803T1 (hr) 2022-03-04
HUE056570T2 (hu) 2022-02-28
LT3612237T (lt) 2022-01-25
AU2018253958B2 (en) 2024-03-07
IL270032A (da) 2019-12-31
EP3612237B1 (en) 2021-09-01
ES2900560T3 (es) 2022-03-17
SI3612237T1 (sl) 2022-02-28
EP3973996A1 (en) 2022-03-30
GB201706394D0 (en) 2017-06-07
IL270032B1 (en) 2024-11-01
IL270032B2 (en) 2025-03-01
CN110769860B (zh) 2024-03-08
US20240350661A1 (en) 2024-10-24
PL3612237T3 (pl) 2022-02-14
US11964027B2 (en) 2024-04-23
JP7443063B2 (ja) 2024-03-05
AU2018253958A1 (en) 2019-11-21
PT3612237T (pt) 2021-12-02

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
CL2018000524S1 (es) Golilla
EP3589248A4 (en) CRYOTHERAPIES
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3697802A4 (en) TRITERPENIC SAPONIN ANALOGUES
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
EP3634397A4 (en) HETEROCYCLYL-POLYMETHINIR-IR-CHROMOPHORE
EP3721165C0 (en) MILITARY CHARGE
EP3654852A4 (en) TOURNIQUET
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
EP3611402A4 (en) SERVO CYLINDER
EP3615471A4 (en) PLASMA PHOTOELECTRONIC IMMUNE SENSOR
EP3669219C0 (en) NETWORK SCALE
EP3714787A4 (en) BIOSENSOR
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
EP3689701A4 (en) BOGIE
EP3687383C0 (fr) Electrogustometre
FI11529U1 (fi) Ontelolaatan kannake
DK3510051T3 (da) Carboxylalkylchitosan
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse